Regulatory approval

Published by the Health Service Executive. Approved

Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy

This is written in the approval document.

Reimbursement

CDS

Citation

Olaparib (Tablet) Monotherapy, 2025, version number 5b, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6397/588_V5b_olaparib_tablet_monotherapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
HSE (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
HSE (1)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
HSE (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
HSE (1)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
HSE (1)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
HSE (1)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
HSE (1)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
HSE (1)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
HSE (1)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
HSE (1)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
HSE (1)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2020-12-01	Health Service Executive	Indication approved for reimbursement.